CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type (Acute CINV, Delayed CINV, Anticipatory nausea and emesis and Breakthrough CINV/Refractory CINV), By Drug Class (Dopamine Receptor Antagonists (Metoclopramide, Chlorpromazine, Prochlorperazine, Haloperidol, Droperidol and Others), Serotonin (5-HT3) receptor Antagonists (Ondansetron, Granisetron, Palonosetron, Dolasetron and others), Substance P/NK-1 Antagonists (Aprepitant, Fosaprepitant, Netupitant, and Others), Corticosteroids (Dexamethasone and Methylprednisolone) and others), By Route of Administration (Oral, Parenteral and Transdermal Patch), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI5823
Pages :266
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market over the forecast period. North America holds 44.6% of the market share, due to increasing adoption of inorganic strategies such as distribution and supply agreements by key players in North America region. For instance, in May 2022, Knight Therapeutics Inc., a Canada-based specialty pharmaceutical company, through one of its wholly-owned subsidiaries, and Helsinn Healthcare SA, a global biopharma company, announced that they had entered into an exclusive license, distribution, and supply agreement for AKYNZEO oral/IV (netupitant/palonosetron/ fosnetupitant/palonosetron) in Canada, Brazil, Argentina, Uruguay, and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. AKYNZEO is 5-HT3 and NK1 receptor antagonist fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. ALOXI solution for injection is marketed in Canada for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy and highly emetogenic cancer chemotherapy, including high-dose cisplatin in adults. Under the terms of the agreement, Knight Therapeutics Inc. will have the exclusive right to distribute, promote, market, and sell the products in the licensed territories.